Met Life Investment Management, LLC Cin Cor Pharma, Inc. Transaction History

Met Life Investment Management, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Jun 14, 2023	BUY	$10.75 - $29.84 $123,162 - $341,876	11,457 New	11,457 $140,000
Q3 2022 May 10, 2024	BUY	$19.9 - $38.94 $67,003 - $131,110	3,367 Added 41.62%	11,457 $320,000
Q3 2022 Jun 14, 2023	BUY	$19.9 - $38.94 $227,994 - $446,135	11,457 New	11,457 $320,000
Q3 2022 Mar 22, 2023	BUY	$19.9 - $38.94 $67,003 - $131,110	3,367 Added 41.62%	11,457 $320,000
Q3 2022 Nov 14, 2022	BUY	$19.9 - $38.94 $67,003 - $131,110	3,367 Added 41.62%	11,457 $376,000
Q2 2022 Jun 20, 2023	BUY	$13.67 - $25.74 $110,590 - $208,236	8,090 New	8,090 $152,000
Q1 2022 May 10, 2024	BUY	$14.13 - $28.49 $114,311 - $230,484	8,090 New	8,090 $141,000
Q1 2022 Jun 20, 2023	BUY	$14.13 - $28.49 $114,311 - $230,484	8,090 New	8,090 $141,000
Q1 2022 Mar 22, 2023	SELL	$14.13 - $28.49 $47,575 - $95,925	-3,367 Reduced 29.39%	8,090 $141,000
Q1 2022 May 12, 2022	BUY	$14.13 - $28.49 $114,311 - $230,484	8,090 New	8,090 $142,000

Ticker CINC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,764,300
Description
CinCor Pharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of drugs for the treatment for cardio-renal diseases. It is involved in developing CIN-107, which is in Phase II clinical trial for the treatment of hypertension, primary aldosteronism, and other cardio-renal diseases, as well as in Phase I clinical trial...

Get notified when there are updates to the investment portfolio of Met Life Investment Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Met Life Investment Management, LLC with notifications on news.